The clinical significance of sentinel lymph node micrometastasis in breast cancer Neill PataniKefah Mokbel Review 20 April 2008 Pages: 393 - 402
Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis W. L. LuL. JansenG. H. De Bock Review 18 April 2008 Pages: 403 - 412
Treatment of metastatic breast cancer: looking towards the future Surabhi AmarVivek RoyEdith A. Perez Review 09 May 2008 Pages: 413 - 422
Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis Mehran HabibiMaciej KmieciakMasoud H. Manjili Preclinical Study 20 April 2008 Pages: 423 - 431
Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay Qi YuYun NiuYuRong Shi Preclinical Study 20 April 2008 Pages: 433 - 440
Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors Gary M. K. TsePhilip C. W. LuiPuay-Hoon Tan Preclinical Study 29 April 2008 Pages: 441 - 448
Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure Lucia CostantinoMaria G. CatalanoNicoletta Fortunati Preclinical Study 25 April 2008 Pages: 449 - 456
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives A-Yong CaoJuan HuangZhi-Ming Shao Preclinical Study 30 April 2008 Pages: 457 - 462
A pilot genome-wide association study of early-onset breast cancer Muhammad G. KibriyaFarzana JasmineHabibul Ahsan Preclinical Study 08 May 2008 Pages: 463 - 477
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients Isabel ChirivellaBegoña BermejoAna Lluch Clinical trial Open access 08 May 2008 Pages: 479 - 484
Analysis of dermatologic events in patients with cancer treated with lapatinib M. E. LacoutureS. M. LaabsK. L. Blackwell Clinical trial 04 July 2008 Pages: 485 - 493
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women J. MurrayO. E. YoungJ. M. Dixon Clinical Trial 26 April 2008 Pages: 495 - 501
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer Vivien H. C. BramwellGordon S. DoigAnn F. Chambers Clinical Trial 25 April 2008 Pages: 503 - 511
The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer Maysa M. Abu-KhalafLyndsay Harris Invited Commentary 02 August 2008 Pages: 513 - 515
High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome Pamela J. GoodwinMarguerite EnnisNicky Hood Epidemiology 25 April 2008 Pages: 517 - 525
Time-varying pattern of recurrence risk for Chinese breast cancer patients Wenjin YinGenhong DiZhimin Shao Epidemiology 19 April 2008 Pages: 527 - 535
Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective Marc SchegerinAnna N. A. TostesonBrian W. Pogue Epidemiology 25 April 2008 Pages: 537 - 547
Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history Megan L. WelshDiana S. M. BuistChristopher I. Li Epidemiology 25 April 2008 Pages: 549 - 558
DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study Meng Hua TaoPeter G. ShieldsJo L. Freudenheim Epidemiology 08 May 2008 Pages: 559 - 568
‘Weighing in’ on screening mammography David BerzWilliam SikovSherry Weitzen Epidemiology 20 May 2008 Pages: 569 - 574
Mutations of the MYH gene do not substantially contribute to the risk of breast cancer Mario E. BeinerWilliam W. ZhangSteven A. Narod Epidemiology 04 May 2008 Pages: 575 - 578
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects Heather-Jane AuKamran GolmohammadiPhilip Jacobs Epidemiology 29 April 2008 Pages: 579 - 587
Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC) Sang Gyu LeeYoung Geon JeeJae Hong Seo Clinical Trial 25 April 2008 Pages: 589 - 595
Cost effectiveness, chemotherapy, and the clinician Jennifer J. GriggsMelony E. S. Sorbero Invited Commentary 10 August 2008 Pages: 597 - 598
Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis Massimiliano CazzanigaTarik GheitMassimo Tommasino Brief Report 09 May 2008 Pages: 599 - 605